Back to Awarded Treatment Trials
Awarded Trial: 07TGF-1097
Grant ID
07TGF-1097
Illness
Schizophrenia
Primary Drug/Intervention
Bexarotene
Primary Dosage
75 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Lerner
Sample Size
90
Duration of Study Period for Each Subject
6 weeks
Outcome Measurements
PANSS, CGI, Simpson-Angus, CDSS, GAF, QLS, ESRS
Results
Bexarotene, a synthetic retinoid used to treat some cancers, was used as an adjunct to treat schizophrenia. 90 patients were given bexarotene 75 mg/d. or placebo for 6 weeks. 79 completed the study. Patients receiving bexarotene had a significant improvmenet on the PANSS positive subscale (p,.001) and on the Global Assessment of Functioning (p,.001). This thus confirms a previous smaller study.
Publication
Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS. The Retinoid X Receptor Agonist Bexarotene Relieves Positive Symptoms of Schizophrenia: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial. J Clin Psychiatry. 2013 Dec;74(12):1224-32.
Link
http://www.ncbi.nlm.nih.gov/pubmed/24434091
PI Name
Vladimir Lerner
Degree
MD
Center
N/A
Institution
Ben Gurion University of the Negev
Address
str. HaTsadik MiYerushalaim, 2
City or Town
Be'er Sheva
State or Province
N/A
Zip or Postal Code
84170
Country
Israel
Email Address
lernerv@bgu.ac.il